You are here

• Home
• Therapy Areas
• Gastrointestinal

• A single-centre, open, two-way cross-over, comparative study of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily regarding 24-hour intragastric pH following single and repeated oral administration in patients with symptoms of GERD

Disease

gastrointestinal diseases

Drug Name

Nexium

Generic Name

esomeprazole

Sponsor

AstraZeneca

Drug Status

Approved Medicine

Phase

I

Start Date

Sep 21, 2001

Study Name

SH-QBE-0091

Study Id

SH-QBE-0091

ClinicalTrials.gov ID

Not Applicable

Recruiting Status

Closed

Protocol Status

Not Available

Report

Jan 18, 1971

• SH-QBE-0091.pdf (216 KB)

Page tools

• Print
• Bookmark this page